Skip to content

Urea treatment of hyponatremia in subarachnoid hemorrhage

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-518532-36-00
Acronym
38RC19.189
Enrollment
52
Registered
2024-11-29
Start date
2020-10-15
Completion date
2025-03-13
Last updated
2024-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyponatremia during subarachnoid hemorrhage

Brief summary

Change in natraemia in mmol/L measured before and on day of treatment discontinuation

Detailed description

Compare the sodium intake required to correct natraemia, Study the mechanism of action of urea, Évaluer l’impact du traitement sur la durée de séjour, Évaluer l’impact du traitement sur le devenir neurologique à 3 mois de l’inclusion, Assessing adverse effects of treatment, Persistence of natraemia correction 48H after discontinuation of treatment, Comparison of speed of correction of natraemia

Interventions

DRUGergytonyl placebo
DRUGUrea

Sponsors

Centre Hospitalier Universitaire Grenoble Alpes
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Change in natraemia in mmol/L measured before and on day of treatment discontinuation

Secondary

MeasureTime frame
Compare the sodium intake required to correct natraemia, Study the mechanism of action of urea, Évaluer l’impact du traitement sur la durée de séjour, Évaluer l’impact du traitement sur le devenir neurologique à 3 mois de l’inclusion, Assessing adverse effects of treatment, Persistence of natraemia correction 48H after discontinuation of treatment, Comparison of speed of correction of natraemia

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026